Intraperitoneal (i.p.) and intracavity administration of antitumour drugs has been performed since the early days of modern cancer chemotherapy. Intraperitoneal infusion of an appropriate cytotoxic agent is still in many patients the most efficient palliative therapy for malignant ascites arising from carcinomatosis peritonei (Weisberg et al., 1955 : Clarkson et al.. 1964 : Suhrland & Weisberger. 1965 Casper et al.. 1983 ). The ability to deliver drugs into the abdominal cavity on a regular or continuous basis has frequently been frustrated by the non-availability of a safe delivery system. High complication rates due to catheter flow obstruction, infection and abdominal pain or discomfort (Piccart et al., 1985) have limited the use of this route of administration. Similarly, available carrier solutions tend to be rapidly absorbed, thus making peritoneal exposure to the drugs patchy and erratic.
Up to 2 1 of fluid is required for adequate immersion of all peritoneal areas liable to bear tumours (Wahl et al., 1989) . Thus. continuous. peritoneal coverage requires frequent regular administration of large volumes of electrolyte solution. which may result in fluid overloading and or unacceptable excretion of massive urine volumes.
Continuous. ambulatory peritoneal dialysis (CAPD) has revolutionised our knowledge. experience and ability to employ the peritoneal cavity for therapeutic purposes. and anephric patients have now been maintained on CAPD for up to 15 years (Bengmark. 1989) . From these developments have come proven. safe delivery systems which protect the patient from peritonitis (Verger & Luzar, 1986; Rottembourg et al.. 1987) and new carnrer solutions. based on the use of glucose polymers as osmotic agents. which remain within the peritoneal cavity for 24 h with minimal exchanges of fluid or electrolytes (Mistry et al.. 1985 (Mistry et al.. . 1987 peritoneal tumour deposits to cytotoxic agents.
Previous studies (Speyer et al.. 1981 : Speyer. 1985 : Sugarbaker et al.. 1985 : Ekberg et al.. 1988 : Goldberg et al.. 1988 : Sugarbaker. 1991 : Hallenbeck et al.. 1992 have shown that 5-FU has single-agent activity in the treatment of the colorectal carcinomas confined to or recurrent in the peritoneal cavity and has a large pharmacokinetic regional advantage following i.p. instillation. i.e. the drug is cleared much more rapidly from the systemic circulation than from the pertoneal cavity.
Recently. it has been shown that prolongation of intravenous infusion (e.g. to 10 weeks) of 5-FU is associated with an increased response rate in patients with advanced colorectal carcinoma (Seifert. 1975 : Lokich et al.. 1989 : Leichman et al.. 1993 The blood and peritoneal dialysate samples were kept on ice, spun at 2.000 r.p.m. for 5 min and the plasma separated and then frozen at -20'C until analysis. Plasma 5-FU concentrations which are below quantitative determination limit (50 1g I-') of the HPLC method were measured by a sensitive and specific gas chromatography (GC) -negative ion chemical ionisation mass spectrometry (NICIMS) method as previously described (Bates et al.. 1991) found to be 15.8 ± 5.6 ml min '. whereas a value of 15.6 ± 5.2 ml min-' was found when calculated as the conventional doselperitoneal AUC ratio. a-phase half-life values are respectively 1.28 ± 0.21 and 1.28 ± 0.15 for peritoneal and plasma compartments, and 5-FU apparent elimination constants are similar in both compartments (0.51 ± 0.02 and 0.56 ± 0.04 in peritoneum and plasma respectively).
Total body clearances (expressed as total absorbed dose plasma AUC ratio) varied between 5 and 261 min-' (Table   III) .
Peritoneal fluid balance profile Dunrng the whole study a total of 344.55 1 (or kg) of carrier solution was instilled (ranging from 29.75 to 125.00 1 per patients) and 344.91 1 (or kg) was drained (ranging from 15.95 to 138.36 1 per patient). For the two patients undergoing long-term i.p. dialysis ( Figure 3 ) the volume balance percentages after 24 h exchanges were mostly stable with time and ranged from 0 to -50% (which means that for 2 1 of carrier solution with 5-FU instilled 2-3 1 were drained 24 h later). This was not associated with electrolyte disturbance or dehydration.
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C}ytology
For each weekday specimen, the total white cell count and the percentages of mesothelial cells, neutrophil polymorphs, macrophages, eosinophils and lymphocytes were monitored.
The percentages of mesothelial cells, macrophages, eosinophils and lymphocytes did not differ significantly from those observed in patients starting CAPD (Fok et al., 1989 (Goldberg et al., 1988) . Furthermore, the novel camrer solution did not affect the 5-FU pharmacokinetic paraneters compared with previous studies with other carrier solutions (1.5% dextrose dialysate or lactated Ringer's solution) (Speyer et al., 1980 (Speyer et al., , 1981 Demicheli et al., 1982; Arbuck et al., 1986; Campora et al., 1987; Schilsky et al., 1990; Sugarbaker et al., 1990 ). The relatively constant peritoneal fluid balance achieved with this new carrier solution ensures maximal coverage of peritoneal areas liable to bear tumours for 24 h. This allows a single daily exchange, which is a much more viable prospect for prolonged out-patient dialysis than some of the schedules previously used (for example eight 4-hourly exchanges repeated monthly) (Speyer et al.. 1980 (Speyer et al.. . 1981 Arbuck et al.. 1986 ). The constant peritoneal fluid balance achieved with the carrier solution combined with the 'state of the art peritoneal twin-bag delivery system gives long-term and feasible access to the peritoneal cavity with no incidence of exit site infection and bacterial peritonitis in this feasibility study.
Based on the pharmacokinetic parameters from the present study we have designed a loading dose infusion schedule in an attempt to maintain steady-state i.p. 5-FU levels.
We have initiated a multicentre phase I study in collaboration with ML Laboratories to determine the maximum tolerable dose (MTD) values for continuous long-term i.p. treatment for 3 months in patients with advanced colorectal. gastnc and ovanran cancer.
